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Abstract: The pharmacological relevance of ODNs forming G-quadruplexes as anti-HIV agents
has been extensively reported in the literature over the last few years. Recent detailed studies
have elucidated the peculiar arrangement adopted by many G-quadruplex-based aptamers and
provided insight into their mechanism of action. In this review, we have reported the history of a
strong anti-HIV agent: the 6-mer d(TGGGAG) sequence, commonly called “Hotoda’s sequence”.
In particular, all findings reported on this sequence and its modified sequences have been discussed
considering the following research phases: (i) discovery of the first 5′-modified active d(TGGGAG)
sequences; (ii) synthesis of a variety of end-modified d(TGGGAG) sequences; (iii) biophysical and
NMR investigations of natural and modified Hotoda’s sequences; (iv); kinetic studies on the most
active 5′-modified d(TGGGAG) sequences; and (v) extensive anti-HIV screening of G-quadruplexes
formed by d(TGGGAG) sequences. This review aims to clarify all results obtained over the years on
Hotoda’s sequence, revealing its potentiality as a strong anti-HIV agent (EC50 = 14 nM).
Keywords: anti-HIV agent; G-quadruplex; aptamer; Hotoda’s sequence; modified sequences
1. Introduction
Guanine quadruplexes (G4s) are a class of non-canonical nucleic acid structures that have attracted
considerable attention thanks to their structural stability under physiological conditions. This class is
characterized by an extensive conformational polymorphism that amplifies its biological potentialities.
Different G4 topologies have been identified by variations in strand stoichiometry and polarity, as well
as by the nature and length of loops and their location in the sequence [1,2].
The increasing interest in the G4 role in gene regulation and its active role in telomerase
maintenance has highlighted the biological relevance of G4 structures [3–5]. A large variety of potential
G4s have been identified in the human genome that could perform important biological roles [6–8].
In addition to humans, G-quadruplexes have been found in other mammalian genomes [9], yeasts [10],
protozoa [11], bacteria [12,13] and viruses [14].
During the last few years, G4s able to recognize and bind specific molecules acting as aptamers
have been developed. In this regard, the peculiar arrangements of G-quadruplexes seem to be a crucial
requirement for aptamer recognition, thanks to the elevated specificity and selectivity of G4 structures.
G-quadruplexes have been exploited for therapeutic strategies as anti-HIV agents, and they have been
successfully designed to target the HIV virus at different stages of its life cycle. The potential targets of
HIV infection are HIV-1 reverse transcriptase, HIV RNase H, HIV-1 integrase (IN) and the viral surface
glycoprotein known as gp120 [14,15]. Among the first-discovered G-quadruplex aptamers targeting the
gp120 glycoprotein as a primary target and the HIV-1 integrase was the parallel-stranded G-quadruplex
T30177 (ZintevirTM developed by Aronex Pharmaceuticals in 1996), which showed high inhibition at
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nanomolar levels (IC50 = 100 nM) [16]. Subsequently, similar to Zintevir, other G-quadruplex aptamers,
such as T30923 [17] and 93del [18,19] and the phosphorothioate ISIS-5320 [20], have been proven
effective at inhibiting the HIV-1 virus. Interestingly, many researchers have discovered that anti-HIV
G-quadruplexes adopt a parallel G4 arrangement.
In this context, in the 1990s, a group of Japanese researchers encouraged by recent discoveries
concerning anti-HIV aptamers forming parallel G-quadruplexes reported an anti-HIV study on
ODNs in which the 5′-end was covalently linked to a 4,4′-dimethoxytriphenylmethyl (DMT) residue.
This discovery was facilitated by easy access to DMT-modified ODNs that are generally obtained as
intermediate products of automated DNA synthesizers [21,22].
This study represents the “mother-generating” of the history of Hotoda’s sequence, because,
for the first time, the active sequence d(5
′DMTTGGGAGGTGGGTCTG3
′
) (SA-1042) was discovered,
along with the importance of the 5′ end modification for the expression of anti-HIV activity. Subsequent
studies highlighted that the active sequence was the 5′-end tract of SA-1042, d(5′DMTTGGGAG3′ ),
identified as SA-1080 [23]. Since then, many modifications have been proposed for d(TGGGAG),
the lead sequence commonly named “Hotoda’s sequence” (Figure 1a).
In this review, a critical overview of all data reported from 1994 through to today about anti-HIV
aptamers based on Hotoda’s sequence has been presented. The goal is to clarify the relationship
between the anti-HIV activity and the nature of the modified sequences studied during these
years, as well as the evolution of associated knowledge from the 1990s, when these special G4
structures were discovered, until today. This paper also explains that through the comparison of
thermodynamic and kinetic studies with biological assays, it was possible to understand the G4
behavior of modified sequences, and only in recent studies has the strong anti-HIV activity of Hotoda’s
sequence d(TGGGAG) been discovered (EC50 = 14 nM).
2. The Discovery of the First 5′-End Modified of Hotoda’s Sequence: d[DMT-(TGGGAG)]
and R-95288
In the 1990s, the active sequence d(TGGGAG) conjugated with a DMT group at the 5′-end
was identified as being able to inhibit the HIV-1 virus in the micromolar range (Figure 1b, SA-1080,
IC50 = 1.0 µM) [23]. Additionally, the mechanism of action against the virus was reported. In fact,
the modified hexamer was able to inhibit the binding of the glycoprotein gp120 to its receptor CD4
molecule, blocking the early stage of the HIV-1 infection process.
The 6-mer d(TGGGAG) was defined as an aptamer able to recognize and bind both the V3 loop
and the CD4-binding site on viral gp120. In this paper, the authors described the structural requirement
of the modified ODN for exhibiting anti-HIV activity that consists of the DMT group conjugation at
the 5′-end of the sequence and the importance of at least three consecutive guanine residues, which are
essential for the formation of a guanine cluster. At that time, the formation of a G4 structure by the
DMT conjugated d(TGGGAG) sequence had not yet been identified. In this context, also very recently,
Zeye H. and co-workers [24] reported a deepened study on the aptameric recognition of some 3′-end
modified G4s based on the d(5
′DMTTGGGAG3
′
) sequence with HIV-1 glycoproteins gp120 and gp41.
The authors demonstrated, using Surface Plasmon Resonance analyses, an enhanced interaction of
these inhibitors with respect to the lead sequence used [d(5
′DMTTGGGAG3
′
)].
In the same years, Hotoda and co-workers reported the synthesis of a mini-library based on the
5′-phosphodiester of d(TGGGAG) conjugated with different aromatic residues. From the anti-HIV
screening of different modified 6-mer ODNs, no more active modified sequences were discovered [25].
Meanwhile, the same researchers reported the synthesis and anti-HIV-1 activity of a mini library of
d(TGGGAG) with a 5′,3′-bis-conjugated lead sequence, wherein the 5′-end conjugation was carried
out by an ether bond and the 3′-end by a phosphodiester bridge [26]. Among the various 3′- and
5′-end-modified 6-mers tested, the researchers identified a potent inhibitor, R-95288, with high
anti-HIV-1 activity (IC50 = 1.0 µM) and low toxicity. The 6-mer (R-95288) bearing a 3,4-DBB group at the
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5′-end and a 2-hydroxyethylphosphate group at the 3′-end was also the most stable when incubated
with mouse or human plasma.
To explore the anti-HIV activity and stability in the human plasma of R-95288, some modifications
at phosphate groups (phosphorothioate, phosphoramidate and methylphosphonate bonds) were
proposed by Koizumi et al. [27]. The findings confirmed major activity of the natural phosphate
R-95288, even though major stability was found for some phosphorothioate derivatives.
Figure 1. Schematic representation of: (a) Hotoda’s sequence; (b) its first 5′-end modified sequences
with strong anti-HIV activity (IC50) [23,28].
Only with a SAR study conducted on a similar family of oligonucleotides was the most potent
anti-HIV agent finally discovered: a performing version of R-95288 containing only the modification
of a 3,4-DBB group at the 5′-end (Figure 1b, R-95288, IC50 = 0.37 µM) [28].
In addition, in this study, it was determined that the anti-HIV-1 activity of modified sequences first
requires conjugation with an aromatic substituent of adequate size at the 5′-end and the formation of
stable G-quadruplex structures that, in agreement with findings for ISIS 5320, could play an important
role in aptamer recognition [20,29].
In this context, with the discovery of the R-95288 aptamer, the CD profiles of modified sequences
were characterized, together with melting temperature analyses. The parallel topology of the G4
structures based on the R-95288 sequence and other modified d(TGGGAG) sequences was attributed
on the basis of the characteristic positive maximum at 260 nm and the negative minimum close to 240
in the relative CD spectrum.
Subsequently, some modification of guanines within this sequence have been reported.
In particular, Koizumi et al. described the N2-methylation of guanine, which mainly led to
enhancements of the G-quadruplex thermal stability [30]. In contrast, the modification proposed by
Jaksâ consisting of the replacement of dG residues with non-natural 8-aza-3-deaza-2′-deoxyguanosine
monomers led to a significant decrease in antiviral activity [31].
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Biophysical and NMR Studies on Hotoda’s Sequence and Its Modified Sequences
An interesting study that aimed to explore possible relationships between the specific effects
induced by terminal groups and both the thermodynamic and kinetic aspects of G-quadruplex
formation was reported by D’Onofrio et al. [32].
Considering the inactivity of Hotoda’s d(TGGGAG) sequence and the low antiviral activity found
for 5′-modified d(TGGGAG) sequences with small aromatic residues [28], the authors supposed that
the antiviral activity was therefore attributed to the presence of large aromatic groups at the 5′-end,
which are able to better stabilized G-quadruplex structures by hydrophobic interactions. DSC and
CD characterization carried out on a set of active 5′-modified d(TGGGAG) sequences suggested a
correlation between the G4-stability, rate of G4 formation and anti-HIV activity of 5′-modified ODNs.
In particular, they examined conjugation at the 5′-end with DMT, tert-butyldiphenylsilyl (TBDPS) and
3,4-dibenzyloxybenzyl (DBB, R-95288 sequence) groups. Biophysical characterization disclosed that
even if the natural sequence forms a G-quadruplex structure, the structure presents a lower thermal
stability (Tm = 41 ◦C) with respect to G4s based on 5′-modified sequences. The authors concluded that
large aromatic groups play a crucial role in the enhancement of thermal stability, supposing that the
kinetics of G-quadruplex folding can also be influenced by these groups. These two factors are reputed
to be responsible for the strong anti-HIV activity.
An NMR study was also carried out on Hotoda’s sequences in 2012 by Virgilio and co-workers,
who observed the coexistence of multiple species supposed to be higher-order aggregates that could be
favored by the formation of a 3′-end G-tetrad [33]. The authors solved the NMR experimental problem
by the introduction of a thymine residue at the 3′-end, which avoids the formation of aggregates and
permits the characterization of the unique G4 adopted by the unmodified Hotoda’s sequence.
Unfortunately, they did not characterize the active aptamer with the DMT group at the 5′-end
because of the lipophilicity of this aromatic group, which also prevented the formation of an
investigable unique G-quadruplex structure, even with the addition of a 3′-end thymine residue.
Finally, in this NMR study, the researchers mainly described, for the first time, the formation of an
A-tetrad between the G-tetrads of Hotoda’s d(TGGGAG) sequence.
3. Modified d(TGGGAG) Hotoda’s Sequences
3.1. End-Phosphodiester ODN Conjugates Based on Hotoda’s Sequence
In these years, D’onofrio et al., investigated the end-conjugation with sugars for the d(TGGGAG)
sequence as a strategy to improve the pharmacological profile of these oligonucleotides [34]. On the
basis of thermal denaturation studies on the resulting G-quadruplexes, they reported that especially
the insertion of a mannose residue at the 3′-phosphate end improves the stability of the G-quadruplex
complex and confers anti-HIV activity to the unmodified sequence. In contrast, 5′-tethering with the
same monosaccharides in all cases decreases both the G-quadruplex stability and the antiviral activity.
These studies underlined the crucial role of aromatic groups at the 5′-end.
In this context, since 2011, aiming to expand the repertoire of potential end-modified d(TGGGAG)
aptamers, Di Fabio and co-workers reported a series of modified d(TGGGAG) conjugated with
aromatic and non-aromatic groups at the 5′-end by a phosphodiester bond (Figure 2) [35,36].
The main goal was understanding the role of the 5′-end group in G4 folding and in the anti-HIV
activity. They reported that both aromatic and non-aromatic 5′-end-modified sequences formed parallel
tetramolecular G-quadruplexes with increased thermal stability (Tm = 57–90 ◦C), but not all sequences
showed high anti-HIV activity (Figure 2).
These results called into question what had previously been reported by D’Onofrio (2007)
regarding the strong dependence between the G4 thermal stability and the anti-HIV activity [32].
In fact, this paper claimed that the major stability of the investigated G4 complexes was not directly
correlated with their pronounced anti-HIV activity.
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However, more importantly, the authors discovered a more active modified Hotoda’s sequence
conjugated with a p-benzyloxyphenyl group (PBP) at the 5′-end and endowed with anti-HIV activity
in the nanomolar range (Figure 2, EC50 = 61 nM). Subsequently, following the same synthetic approach
of Di Fabio et al., a 5′-end cholesteryl-HEG (hexaethylene glycol) derivative of Hotoda’s sequence was
reported, but the anti-HIV activity of the sequence was not evaluated [37].
Figure 2. Anti-HIV activity (EC50), thermal stability (Tm) and ∆Tm (the difference between the Tm of
modified sequence and that of the natural one) of some 5′-end modified d(TGGGAG) sequences [35,36].
3.2. Modifying the Nucleobases of the d(TGGGAG) Sequence
Following the results reported by Di Fabio and co-workers, several publications reported the
synthesis and biophysical and biological characterization of new modified Hotoda’s sequences created
by remodeling the nucleobases of the sequence. Pedersen et al. described how the incorporation
of LNA (locked nucleic acids) or INA/TINA monomers (intercalating nucleic acids and twisted
intercalating nucleic acids) that present pyrene bearing moieties (Figure 3a) into terminal and internal
positions of the sequence influences both the G-quadruplex arrangement and the anti-HIV activity of
the 5′-end DMT Hotoda’s sequence [38].
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The study data confirmed the relevancy of the 5′-end DMT group in the anti-HIV activity
and pointed out that the incorporation of an LNA monomer enhances both the thermal stability
of G-quadruplex structures and the anti-HIV activity. Moreover, the insertion of a pyrene-bearing INA
moiety alters the G4 arrangement, resulting in inactive compounds, whereas the TINA monomer was
found to enhance the activity.
In the same year, Chen et al. also reported a brief study on Hotoda’s sequences modified at the
5′-end thymidine nucleobase with TBDPS groups. The study reported high anti-HIV activities of
the new modified sequences, identifying a new position for the conjugation of hydrophobic groups
(Figure 3b, I, IC50 = 0.33 µM) [39].
Figure 3. Schematic representation of the modified Hotoda’s sequences at nucleobases: (a) insertion of LNA,
INA and TINA monomers in different position of d(TGGGAG) sequence [38]; (b) the most active modified
d(TGGGAG) sequences with the insertion of aromatic groups at 5′-end thymidine nucleobase [39,40].
An extension of this paper was recently reported by the same research group [40]. The authors
elucidated the synthesis and introduction into Hotoda’s sequence of new nucleoside analogues
by modifying the base with a hydrophobic p-benzyloxyphenyl group. All nucleobase-modified
d(TGGGAG) sequences showed moderate anti-HIV activities (Figure 3b, II, IC50 = 0.78 µM).
3.3. Monomolecular and Bimolecular G-Quadruplexes Formed by Modified Hotoda’s Sequences
Aiming to improve the kinetics of G4 folding, Oliviero et al. reported the synthesis of
tetra-end-linked oligonucleotides (TEL-ODNs) forming monomolecular G4s based on Hotoda’s
sequence [41]. These new structures presented a special linker at the 3′-end that promotes the formation
of a parallel monomolecular G4 structure with respect to the tetramolecular G4 formed by Hotoda’s
sequences. This modification mainly provided significant improvement of the G4-folding kinetics,
which were instead very low for tetramolecular structures.
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In addition, the authors confirmed an enhancement of the thermal stability when the 5′-end of
TEL-ODNs is conjugated with a lipophilic group (TBDPS). The anti-HIV data of 5′-end-conjugated
TEL-ODNs based on Hotoda’s sequence (Figure 4a, I, EC50 = 82 nM) disclosed the importance of
kinetic factors, together with conjugation at the 5′-end, in relation to the anti-HIV activity.
Figure 4. (a) G-quadruplex structures of monomolecular TEL-ODNs modified at 5′-end with TBDPS
group (I) and the both 5′-end and internal modified TEL-G4 (II) with a cytosine that replaces the
adenosine base of the Hotoda’s sequence [41,42], (b) Bimolecular G-quadruplex Hairpins with related
anti-HIV activity (EC50) and thermal stability (Tm) [43].
An extension of the TEL-ODNs repertoire was reported in 2012 by the same authors, in which
they synthesized new TEL-ODNs to study the effect of the base sequence on the anti-HIV activity [42].
All new TEL-(TGGGXG)4 aptamers retained potent anti-HIV-1 activity in the nanomolar range.
In particular, the replacement of adenosine by cytosine allows improvement of the anti-HIV activity
(Figure 4a, II, EC50 = 39 nM).
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Di Fabio et al. also reported the synthesis and biophysical characterization of a new family of
modified d(TGGGAG) sequences, the so-called hairpins, that consists of bimolecular d(TGGGAG)
G-quadruplexes conjugated at the 5′-end with aromatic groups (Figure 4b) [43].
The goal was the discovery of more active G4s based on Hotoda’s sequence by modulating the
kinetic and thermodynamic factors of G4 folding. The hairpins are characterized by a hexaethylene
glycol (HEG) linker at the 3′-end and different aromatic moieties at the 5′-end. Strong thermal stability
was found for all hairpins. Moreover, conjugation with a lipophilic group conferred anti-HIV activity
to the sequence (Figure 4b, H2–4). These results confirmed the relevance of 5′-end conjugation in the
anti-HIV activity.
3.4. Kinetics Study and Anti-HIV Screening of the Most Active Hotoda’s Modified Sequences
To clarify what makes these oligonucleotides strong anti-HIV agents and whether the kinetics of
G-quadruplex folding are a critical aspect in the expression of HIV-activity, Romanucci et al. reported
a comprehensive kinetics study on the G4 folding of the most active 5′-end-modified d(TGGGAG)
sequences using electrospray mass spectrometry (ESI-MS) [44].
From this study, they found very slow kinetics for the folding of tetramolecular G-quadruplexes,
together with a strong effect of ODN concentrations (single-stranded concentrations) on the G4-folding
kinetics. In addition, they clarified that both inactive natural Hotoda’s sequences and the most active
5′-end-modified d(TGGGAG) sequences possess the same kinetics, highlighting that the presence of a
5′-end group is not implicated in the kinetics of G4 folding.
Finally, ESI-MS experiments surprisingly revealed the formation of higher-order G4 structures
unambiguously identified as octameric complexes.
In light of these findings concerning the modified Hotoda’s sequence, the same authors designed
an extensive anti-HIV screening of the kinetically studied 5′-end-modified d(TGGGAG) sequences in
comparison with the unmodified Hotoda’s sequence [45]. The experiments were performed by testing
all ODNs at different single-stranded ODN concentrations only after 14 days from the start of the G4
folding process to evaluate the effects of both the time and the ODNs concentration on the amount of
active G-quadruplex specie on the expression of anti-HIV activity.
The anti-HIV activity and cytotoxicity of the ODNs were evaluated against wild-type (WT) HIV-1
strain IIIB and NL4.3, the T30177 (Zintevir)-resistant strain derived from NL4.3 (NL4.3/T30177),
and the dextran sulphate 8000 (DS8000)-resistant strain derived from NL4.3 (NL4.3/DS8000), in MT-4
cell cultures.
In the latter case, the authors aimed to investigate the mechanism of action of these ODNs,
which could be very similar to that reported by Este et al. for Zintevir, thanks to their structural
similitude [16]. From this anti-HIV screening, the authors reported a similar mode of action of Zintevir
for some 5′-end-modified d(TGGGAG) ODNs, suggesting different mechanisms depending on the
modification at the 5′-end of d(TGGGAG) sequences.
Interestingly, they also tested the unmodified Hotoda’s sequence at different initial ODN
concentrations against WT viruses and Zintevir- and DS8000-resistant strains. In this regard,
a significant result reported in this paper was the strong anti-HIV activity of the unmodified Hotoda’s
sequence, which, contrary to extensive reporting over the years by many publications, showed the
highest anti-HIV activity (EC50 = 14 nM).
In detail, the Hotoda’s sequence without any modification and prepared under proper
experimental conditions that favor G4 formation, displayed the highest anti-HIV activity.
The formation of a parallel G-quadruplex structure was confirmed by CD and native gel
electrophoresis analyses.
Finally, the Hotoda’s sequence seems to follow a different mechanism of action with respect to its
associated 5′-end-modified sequences.
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4. Conclusions
In this review, the history, since its discovery in the 1990s, of a potent anti-HIV agent, the so-called
Hotoda’s sequence, has been examined in depth. This sequence was reported to inhibit the primary
target of HIV infection, binding to the envelope glycoprotein gp120 by aptameric recognition
only when conjugated at the 5′-end with a lipophilic group (Figure 1b, R-95288; IC50 = 0.37 µM).
Its significant anti-HIV activity was ascribed to two main factors: the peculiar arrangement in a parallel
tetramolecular G-quadruplex structure and conjugation with a lipophilic group at the 5′-end of the
d(TGGGAG) sequence.
Since this discovery, many groups have focused their research on the synthesis of new and
effective modified Hotoda sequences, aiming at understanding the role of both the lipophilic 5′-end
group and the G-quadruplex arrangement with respect to the strong anti-HIV activity observed.
A biophysical characterization was performed on the first 5′-end-modified sequences, highlighting
that the thermal stability of the resulting G-quadruplexes was higher than that reported for the inactive
natural Hotoda’s sequence. This study suggested the implication of thermal stability in the anti-HIV
activity of modified d(TGGGAG) sequences, but the theory was subsequently confuted by other
investigations of different modified sequences.
Over the years, various very potent modified Hotoda’s aptamers have been found, and the most
active sequences are a tetramolecular G4 based on Hotoda’s sequence and conjugated at the 5′-end
with a p-benzyloxyphenyl group (Figure 2, EC50 = 61 nM) and the monomolecular G4 based on the
d(TGGGCG) sequence conjugated at the 5′-end with a TBDPS group (Figure 4a, EC50 = 39 nM).
In the meantime, various modifications were reported, ranging from the introduction of 5′-
and 3′-end linkers to transform the tetramolecular G-quadruplex arrangement into more kinetically
favourable bimolecular and monomolecular arrangement to modification of the phosphate backbone
and nucleobases. Additionally, the G4 folding kinetics of some active 5′-end-modified d(TGGGAG)
sequences were investigated, highlighting no differences arising from conjugation with a lipophilic
group at the 5′-end.
All these results have led researchers to conduct deepened screening of the anti-HIV activity of
both natural and 5′-end-modified Hotoda’s sequences. Very interestingly, this study revealed the great
potency of Hotoda’s sequence, in disagreement with the conclusion claimed before. The discovery
of the high activity of the unmodified Hotoda’s sequence (EC50 = 14 nM), makes this sequence
one of the most potent G-quadruplex anti-HIV agents today, highlighting how the study of these
supramolecular structures is complex and needs increased attention from researchers. The promise of
Hotoda’s sequence as an anti-HIV agent in upcoming clinical trials is alluring, and the challenges are
considerable, but not insuperable.
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